IceCure Medical Ltd (ICCM) Earnings Call Transcript
November 18, 2026
Earnings Call Speaker Segments
Before we start, let me take a moment to read the disclaimer regarding forward-looking statements. This call, along with the question-and-answer session that comes after it, includes forward-looking statements as defined by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Terms like expects, anticipates, intends, plans, believes, seeks, estimates, and similar expressions or variations of those words are meant to identify forward-looking statements. This conference call carries time-sensitive information and speaks only as of today's live broadcast, November 18, 2026. I'll now hand the call over to IceCure Medical's CEO, Eyal Shamir. Please go ahead.
Thank you, operator, and thanks to all of you for being with us today. Across the first 9 months of 2026, we saw ongoing commercial momentum, especially in the United States, which is our primary commercial market. Total revenue rose 26% year-over-year, and U.S. sales were up 83%, reflecting both the continuing expansion of our commercial activities and growing adoption of process. In the third quarter, we also kept growing our U.S. commercial presence, moved the choice post-marketing study forward, and strengthened the clinical evidence behind prior aviation. In our view, this development shows the progress we are making in turning the clinical and regulatory foundation built over the past several years into commercial growth and model position adoption. Let me begin with our financial and commercial performance in the United States. As of the end of the third quarter of 2026, we had nearly doubled our U.S. commercial footing, going from 11 states at the close of the second quarter of 2025 to 21 states. We brought on dedicated sales and marketing professionals in key regions, among them Neo, Southern California, the Midwest and Provida, plus additional clinical support personnel; this build-out of commercial infrastructure lets us engage small tradition and medical institutions, provide clinical support and training, and support adoption and utilization of process. We believe that combining broader geographic coverage, an expanded commercial team and increased tradition engagement gives us a stronger foundation for our continued U.S. commercial another important area of progress is our colors marketing study, which we designed to generate additional clinical evidence while expanding transition experience with process. Since the study began, we have newly established clinical sites, including West Council Center in German town tuning, advances as Glendon in Ganesan, California and legacy has important argon, and we have started screening and treating patients at participating U.S. centers, with progress from activating our first clinical sites through screening and treating the first patients at worth Clinic Center in Tennessee, and we have since announced initial patients enrolled at participating U.S. clinical. We are also in discussions with additional leading medical centers about potentially taking part in the study. We see choice as closely tied to our older commercial strategy. As additional leading institutions and physicians gain clinical experience with process, the study can generate real-world evidence that supports position confidence and contributes to broader adoption over time. Beyond our commercial and clinical progress in the United States, we continue to expand the regulatory and commercial footprint of Parsons internationally; recent developments include the Gulay approval in China and an inclusive distribution agreement in the Netherlands, further expanding the markets where process can be commercialized. We are also seeing continued interest from physicians and medical institutions in Europe, South America and other international markets as we work to build regulatory and commercial relationships that support broader adoption of process. At the same time, we continue the scientific foundation supporting cryoablation. In Q3, we pointed to 2 more peer-reviewed scientific papers that look at cryoablation's part in de-escalating treatment for breast cancer, including work on early-stage breast cancer and axillary like node matastrophe. Our view is that generating independent scientific evidence on an ongoing basis can do more to help physicians become aware and confident in trial elaboration, and it can keep supporting wider adoption as time goes on. At the same time, we keep reinforcing our intellectual property portfolio as process moves into further markets and into other commercial exposure. We see our IP as a significant strategic asset and stay focused on safeguarding the technologies behind cost as we pursue commercial adoption around the world. All of this together shows the progress we are making in our commercial, clinical and international activity. What we remain focused on is executing on broadening our commercial presence, growing traditional adoption and utilization of process, moving our clinical program forward and building the evidence needed to back all of the adoption. Although we are still at an early stage of realizing the commercial opportunity for persons, we believe the signs we are seeing, especially in the United States, give us a stronger foundation for continued growth. With that, I'll hand the call to our Chief Financial Officer, Meir Peleg, who will go through our financial results in greater detail.
Thank you, Eyal, and good morning to all of you. I'll give a quick rundown of the financial results we posted for the 9 months that ended September 30, 2026. Revenue overall during the first 9 months of 2026 rose roughly 26%, reaching $2.6 million, up from $2.1 million in the same period of 2025. Gross profit came in at about $762,000, an increase of roughly 22%, versus $626,000 a year earlier. As Al noted, we're especially happy with how things went in the United States, where sales climbed 83% year-over-year across the first 9 months of the year; that result mirrors both the ongoing build-out of our commercial dividend and presence's rising standing in the market. Turning to operating expenses, effect and development costs were roughly $6.5 million, compared with $5.1 million in last year's corresponding period. That rise mainly mirrors greater spending tied to the choice post-marketing study as well as other clinical and development work. Sales and marketing expenses grew about 20%, to $3.6 million from $3 million a year earlier, largely mirroring the ongoing build-out of our U.S. commercial operation while U.S. sales grew 83% across that same span. General and sales expenses came to roughly $3.5 million, versus $3.3 million in the corresponding period of 2025. Our operating loss during the first 9 months of 2026 was about $12.9 million, compared with $10.8 million a year earlier. Net loss came to roughly $12.9 million, versus $10.8 million across the first 9 months of 2025. At September 30, 2026, cash and cash equivalents stood at about $8.2 million, compared with roughly $8.9 million at year-end 2025. We keep managing our financial resources prudently while putting money into the commercial, clinical and organizational capabilities we see as essential to backing our long-term growth strategy. Our spending on growing the U.S. commercial organization and on pushing the Choice study forward shows how committed we are to building the infrastructure and clinical evidence needed to support wider adoption of process. With that, I'll hand the call back to the operator so we can open the line for questions.
Thanks, and good morning or afternoon, depending on where you are. I suppose if we begin with revenue, during last year we saw a notable sequential lift in Q4 — do you expect we'll see the same this year? Or is that more of a onetime event?
I've got made, please answer that, and we need chart. I think perhaps Chad will begin, and then I'll add some color for the rest of the world.
Absolutely, and thanks for asking. I can address the United States in particular. We feel we're beginning to gain genuine momentum here in the U.S., and along with that, we would anticipate our sales revenue continuing to rise from one quarter to the next. Meir, would you like to cover the rest of the world?
Yeah, I think we'll show it, and it's also in the square that we've got some revenue right now, while Q3 tends to be weaker than the rest, along with Q1, and Q4 is usually our strongest. I can't say it'll be the same — it was the best — the same as last year, possibly, but it will be better, we assume, of course, definitely better than Q3 2026.
Great. And without providing guidance on 2027, could you discuss what you expect in terms of how the revenue ramp should continue? It sounds like things are picking up, and we should see revenue growth accelerating in 2027. But I just wanted to hear your thoughts on that.
So again, we're not giving guidance, and thank you for the question. It's a good one. We do see acceleration in the sales projection for next year for revenue is a healthy double-digit growth I would say that is weight.
All right, great. So if I could just squeeze in one last question here. Regarding the CHOICE study, what sort of early feedback are you receiving? Are physicians finding it straightforward to climb the learning curve? Just whatever feedback is coming in from these early days.
This is Eyal, and I'll take that one — if anything more is needed, Shaan, our VP Sales for North America, along with our COO, can chime in. As we announced the first 2 sites, 1 of them is being run by Dr. Richard fine along with some of the connect and West Clinic, and Dr. Fine, they're very well experienced. They took part in the II study and handled other cases. Same goes for Veeva California — Dr. Dennis on is among the users, high-volume users of the 1 experience. One of the new sites we announced is by Dr. Natale Johnson from Senate Oregon, a past president of the society. She's among the new users, and she performed some cases prior to the PMS and pace for the PMS; both she enrolled all the patients and, for the users, very easy to use, excellent minimally invasive solutions, so extremely satisfied with the cases she performed.
All right. So at this point, what is the installed base of consoles in the U.S.?
But we — as the revenue growth shows and as we announced, plus new sites, again, we didn't provide guidance last time we talked about the active site, which was in June, and we still have some orders that must ship before the year ends. So I think in a few weeks, or months to 2, we'll share some updated information on that, but we definitely are seeing growth in sales and sites.
All right, good. And just so I understand the CHOICE study — are there 5 sites right now? So, could you address these questions?
Yeah. As of today we have 4 sites, though we anticipate getting some additional sites finalized in the very near future; so since last call we've made really solid progress when it comes to recruiting sites, contracting with those sites, and the commercial side too. So I think you should expect to see new sites being rolled into the study at more of a steady cadence across the next couple of months.
All right, that's great. And the final question concerns the commercial team. If I recall correctly, as of roughly last month or so, it stood at about 7%, and your expectation was 9 by year-end. Does that plan still hold?
Yes. So Ken, as this morning's earnings release shows — actually it came almost a week ago — we brought on excellent experts to support us in Florida. That's an extremely important market, and 2 to 3 months back we had someone in California. Again, an excellent market and a very important one for future growth. We might bring on another 1 before the year is out, or very early next year. And for next year, naturally we plan to expand the team to support the sales growth, as May mentioned, with significant double-digit growth in the U.S.
The first 1 concerns only the CHOICE study; after the second quarter update, we expected the first patient to be enrolled in September, and we saw the update that they were treated back in October. I'm just curious, where does that pipeline stand now? And how do you think — how do you — what's your outlook relative to those deadlines we've discussed previously, where we were expecting 80 patients by the end of March 2027 and then 400 by March 2029. Do you believe you're on track to hit those deadlines?
I'm not certain we'll manage the 400 within the 3 years, because with some of the contract agreement, some of the sites are taking a longer time; earlier this year we had some difficulties traveling, but we are adding more and more, so that they have a pipeline of patients, some of them will join and begin treating patients before the end of the year and very early next year. But I believe we will be able to fill the gap; more sites will be on board, and I know that some of them have been given patients who really fit the trial and are waiting to be treated. At the moment, though, it's too early to say that it will be able to meet the 400 within 3 years or perhaps some short time after that or whatever.
All right, and do you folks have some room to approach the FDA and make that argument, and secure a bit of extra time there?
On that, we're in ongoing dialogue with the FDA; we're also providing them updates. So we will, naturally, talk it over with them regarding where we'd want to see the patient and where they'd want to see the patient, so I'm confident we'll reach a mutual agreement on that.
All right, that's good to hear. Now, regarding the international part of the business, you provided updates on the approvals — both regulatory and IP — in China and with the Netherlands distributor. I'm just wondering: what's your plan for going to market in China? Do you expect to set up a partnership, or a distributor relationship? And once that revenue begins to come in — then my follow-up would be about Japan and Canada. I'd just like to know if we can get an update on the approval time lines there.
Yes. Okay, so let me begin with China. We're currently in discussions with a number of potential partners, mostly in a distribution-type role. In China, naturally, you have to work with them in close partnership, but it will be more of a distribution arrangement. As soon as we have something in place, we'll make a proper announcement at that level. So that's what we're working on. As for Canada, we're waiting on the breast cancer Canada approval, which could come in the next few weeks — perhaps if you allow 2 to 4 months, we expect — we've answered all the questions I had, and we're expecting approval within the next few months. And for Japan, we expect Terumo to make the submission to the Japanese FDA during the first semester of '27.
Thank you all for your questions and for being with us today. Looking forward, our priorities are clear: we want to speed up commercial growth in the U.S., add to and increase use of Protons, move the TROI study forward, and keep building the clinical evidence that supports prior ovation, with U.S. sales rising 83% year-over-year across the first 9 months of 2026, alongside a broader commercial footprint and steady clinical progress; we believe a some foundation is being built for the next phase of Porton's commercialization. Our focus stays on execution and on turning this progress into bolder adoptions and long-term value for our shareholders. Thank you once more for your continued interest and support; we look forward to updating you on our progress.
That brings us to the end of IceCure Medical's conference call on financial results for the third quarter and 9 months of 2026. Thanks for taking part. You can now proceed to disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete IceCure Medical Ltd transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to IceCure Medical Ltd earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.